Cat. No. 2607
Alternative Name: PD 134308
Chemical Name: 4-[[(1R)-2-[[(2R)-3-(1H-indol-3-yl)
Biological ActivityPotent and selective CCK2 (CCK-B) receptor antagonist that displays ~ 1600-fold selectivity over CCK1 receptors (IC50 values are 1.7 and 2717 nM for CCK2 and CCK1 respectively). Has negligible affinity at a range of other binding sites (IC50 > 10 μM). Exhibits anxiolytic activity following oral administration.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Andre et al (2005) Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies. J.Neurosci. 25 7896. PMID: 16135746.
Moody et al (2001) CI-988 inhibits growth of small cell lung cancer cells. J.Pharmacol.Exp.Ther. 299 1154. PMID: 11714907.
Hughes et al (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc.Natl.Acad.Sci.USA 87 6728.
If you know of a relevant reference for CI 988 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses CI 988 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: CI 988, supplier, Potent, selective, CCK2, antagonists, Cholecystokinin2, Receptors, CI988, PD134308, Tocris Bioscience, CCK2 Receptor Antagonist products